Fractional Exhaled Nitric Oxide and CRP Levels in Egyptian Patients With Obstructive Sleep Apnea Syndrome

Obstructive sleep apnea syndrome (OSAS) was associated with upper and lower respiratory tract inflammation, Fractional exhaled nitric oxide (FeNO) proposed as a marker of airway inflammation, few studies were done on the impact of continuous positive airway pressure (CPAP) on FeNO.

Aim of the work: to study the impact of continued positive airway pressure therapy on exhaled NO and using Hs-CRP as a marker of inflammation in obstructive sleep apnea syndrome.

Patient and Methods: This study is a case-control study including participants were newly diagnosed as OSAS and control recruited from sleep outpatient clinic, full night PSG was done, fractional exhaled nitric oxide and Hs-CRP were measured next morning of PSG, CPAP for moderate to severe OSA patient was advised with measurement of FeNO and Hs-CRP after 3months of CPAP Keywords: FeNO; Hs-CRP; CPAP; OSA. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Study Overview

• Status: Completed
• Conditions: OSA
• Intervention / Treatment: Diagnostic test: Fractional exhaled nitric oxide and CRP levels

Detailed Description

This study is a prospective 3 months follow up study including only (27) participants as a convenient sample for the cost limitations newly diagnosed as OSA and (10) healthy control.

inclusion characters All participants enrolled in this study

1. were ≥ 18 years old,
2. non-smokers and
3. excluded from any inflammatory disorders (allergy, bronchial asthma, gastro-esophageal reflux disease, cardiovascular diseases, and cerebrovascular diseases) or use of any regular medication including (nasal/inhaled/oral corticosteroids, antihistaminic, cysteinyl leukotriene receptor inhibitors), or
4. had an upper or lower respiratory tract infection 2 weeks prior to sampling. Control healthy subjects were also free from any sleep disorders symptoms. Cases were recruited from Sleep-disordered breathing unit out Patient Clinic in pulmonary medicine department - Mansoura University - Egypt. All participants in this study were evaluated by history taking with stress on OSAS questionnaires, anthropometric parameters measurement and spirometric pulmonary function (FEV1, FVC and FEV1/FVC ) all patients were subjected to laboratory, attended, full-night polysomnography using (SONMOscreenTMplus, SOMNOmedics, (Germany) with AASM standard montage, This included a standardized montage: two-channel electroencephalograms (EEG; C4/A1, C3/A2), bilateral electrooculogram (EOG), submental electromyogram (EMG), bilateral leg EMGs, and electrocardiography (ECG). Airflow was measured using a thermistor (Healthdyne Technologies), the respiratory effort was assessed by inductance plethysmography and oxygen saturation was recorded using a finger probe. The oxygen saturation signal was digitally sampled at 1 Hz and stored both on the PSG record and in a separate monitor for offline analysis.

studies were interpreted according to the last manual scoring criteria. The cases were diagnosed as severe OSA according to the third international classification of sleep disorders. Then they were classified according to apnea-hypopnea index (AHI) into two main groups: cases (AHI ≥5) (n=) and control (AHI˂5) (n=10). Cases were classified into two subgroups into severe OSA (AHI ≥ 30) (n=34) and moderate OSA (AHI (15-30) mild (n=10).

On the next morning of the study 30 min after PSG, the blood sample was collected for measuring of high sensitivity C- reactive protein (HS-CRP) by (The Immunospec Hs-CRP) ELISA, based on the principle of a solid phase enzyme-linked immunosorbent assay [15]. The assay system utilizes a unique monoclonal antibody directed against a distinct antigenic determinant on the CRP molecule.

1. fractional exhaled nitric oxide (FeNO) measurement: was measured by (NO breath®FeNO monitor-Bedfont scientific Ltd) according to international recommendations [16], with a single breath online method at constant flow of 50 mL/s or 12 seconds of exhalation of adults with a sensitivity of one part per billion (ppb) Calibration of the analyzer was automatically performed by the software. Briefly, after inhaling to total lung capacity, the subjects exhaled through a mouthpiece into an exhalation circuit. All subjects were asked to stop eating, drinking, and strenuous exercise for two hours prior to FeNO measurement.

2. CPAP therapy and follow up: 22 of 27 patients with moderate and severe OSA were advised to use CPAP therapy after full-night CPAP titration study in accordance with AASM recommendations [17]Preliminary education and adaptation for CPAP was performed 1hour prior to the beginning of CPAP titration.

   An optimal titration study was defined as one in which an optimal CPAP pressure was reached that normalizes the AHI and eliminates snoring, desaturation, and arousals, and restores a normal flow contour [17] adjusted prescribed CPAP pressure after titration was administered during sleep for at least five hours per night, for at least five days per week for three consecutive months.

3. follow up sessions after CPAP therapy: were adjusted 1,2 and 3 months after starting CPAP therapy for evaluation of patients response and compliance to CPAP, Adherence to the CPAP therapy was evaluated after revision of the download information from the CPAP device.

   Adherence was defined as CPAP use for an average of 4 h on

   ≥ 70% of the nights.

4. (FeNO) was also measured in the three follow up visit with CPAP follow up, however, BMI, spirometric pulmonary function(FEV1, FVC, and FEV1/FVC ) and high sensitivity C- reactive protein (HS-CRP) were measured after 3 months in last follow up visit of the study.

Five patients from 27 were lost in follow up sessions because they did not use CPAP.

Then data were analyzed using SPSS version 16 for Windows® (SPSS Inc, Chicago, IL, USA). Qualitative variables were presented as numbers and percentages. Chi-square test or Fisher exact test of significance was for comparison between groups, as appropriate. Quantitative variables were presented as mean ±SD. They were tested for normality distribution by the Kolmogorov-Smirnov test. In normally distributed variables unpaired t-test (t) was used. In abnormally distributed variables independent Mann-Whitney test (Z) was used. P-value ≤0.05 was considered statistically significant. For the detection of cut off points, we use the receiver operating characteristic (ROC) curve. Sensitivity, Specificity values were used for studying the selected cut off point for validation as a screening tool.

• Study Type: Interventional
• Enrollment (Actual): 27
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Egypt
  • Mansoura, Egypt
    • Mansoura Faculty Chest Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 58 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

fractional exhaled nitric oxide and Hs-CRP were measured next morning of PSG, CPAP for moderate to severe OSA patient was advised with measurement of FeNO and Hs-CRP after 3months of CPAP

1. were ≥ 18 years old,
2. non-smokers and
3. excluded from any inflammatory disorders (allergy, bronchial asthma, gastro-esophageal reflux disease, cardiovascular diseases, and cerebrovascular diseases) or use of any regular medication including (nasal/inhaled/oral corticosteroids, antihistaminic, cysteinyl leukotriene receptor inhibitors),
4. or had upper or lower respiratory tract infection 2 weeks prior to sampling.
5. Control healthy subjects were also free from any sleep disorders symptoms. Cases were recruited from Sleep-disordered breathing unit out Patient Clinic in pulmonary medicine department - Mansoura University - Egypt.

Exclusion Criteria:

1. smokers
2. inflammatory disorders
3. cardiovascular disease,
4. on regular medication including (nasal/inhaled/oral corticosteroids, antihistaminic, cysteinyl leukotriene receptor inhibitors) -

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Patients; full night PSG (polysomnogram) was done, fractional exhaled nitric oxide and Hs-CRP were measured	Diagnostic test: Fractional exhaled nitric oxide and CRP levels; measurement of FeNO and Hs-CRP after 3months of CPAP
Placebo Comparator: control; CRP level was measured	Diagnostic test: Fractional exhaled nitric oxide and CRP levels; measurement of FeNO and Hs-CRP after 3months of CPAP

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Full-night PSG was performed,	Measurement of FeNO and Hs-CRP with three month intervals of CPAP	one year

Collaborators and Investigators

• Sponsor: Mansoura University

Study record dates

Study Major Dates

• Study Start (Actual): June 6, 2017
• Primary Completion (Actual): August 15, 2018
• Study Completion (Actual): November 20, 2018

Study Registration Dates

• First Submitted: November 19, 2019
• First Submitted That Met QC Criteria: November 25, 2019
• First Posted (Actual): November 27, 2019

Study Record Updates

• Last Update Posted (Actual): December 3, 2019
• Last Update Submitted That Met QC Criteria: November 30, 2019
• Last Verified: November 1, 2019

More Information

Terms related to this study

• Keywords: OSA; CPAP; FeNO; ;;; Hs-CRP
• Additional Relevant MeSH Terms: Nervous System Diseases; Respiratory Tract Diseases; Apnea; Respiration Disorders; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Sleep Apnea Syndromes; Sleep Apnea, Obstructive; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Vasodilator Agents; Autonomic Agents; Peripheral Nervous System Agents; Protective Agents; Bronchodilator Agents; Anti-Asthmatic Agents; Respiratory System Agents; Antioxidants; Free Radical Scavengers; Endothelium-Dependent Relaxing Factors; Gasotransmitters; Nitric Oxide
• Other Study ID Numbers: MS.16.06.82

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No